

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: December 10, 2008
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-38122
(Commission File Number)

59-3410522
(IRS Employer
Identification Number)

13700 Progress Blvd
(Address of principal executive offices)

32615
(Zip Code)

386-418-4018
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01 OTHER EVENTS

On December 10, 2008, Oragenics, Inc. (the “Company”) d/b/a ONI BioPharma Inc.(Alternext US* “ONI”) received notice from Alternext Paris that the admission committee had reviewed the Company’s listing application and upon recommendation by the Company’s listing sponsor Bryan Garnier, among other factors, had admitted the Company to be listed on their exchange.

The trading symbol will be “ALONI” and trading will commence on Alternext Paris on December 15, 2008.

ONI BioPharma is the first United States based company to be listed on the Alternext Paris exchange.

A copy of the press release announcing the listing on Alternext Paris is furnished as Exhibit 99.1 to this Current Report on Form 8-K. We do not intend for the information referenced as being available on our website in the press release to be a part of this Form 8-K.

* The American Stock Exchange was acquired by NYSE Euronext on October 1, 2008, and its name was changed to NYSE Alternext US LLC.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.

<u>Number</u>	<u>Description</u>
---------------	--------------------

99.1	Press release issued December 10, 2008 as to Alternext Paris notice
------	---

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 10th day of December, 2008.

ORAGENICS, INC.

By: /s/ David B. Hirsch

David B. Hirsch
Chief Financial Officer



PRESS RELEASE

ONI BIOPHARMA ANNOUNCES ITS LISTING ON ALTERNEXT PARIS

ONI BioPharma will be the first US company to list on Alternext Paris

PARIS, France, and ALACHUA, Florida, USA (December 10, 2008) - Orogenics, Inc. d/b/a ONI BioPharma Inc. (Alternext US¹: "ONI"), an American biopharmaceutical company that has developed broad-based technologies in oral care, antibiotics, diagnostics and weight control, announced today its additional listing on Alternext Paris. This new listing will make ONI the first US-based company to have its shares traded on Alternext Paris, beginning December 15, 2008.

ONI's Alternext Paris listing is an integral part of the ambitious commercial strategy it has implemented. In particular, ONI has now begun sales in the United States of EvoraPlus[™], its first probiotic that helps maintain dental and oral health, designed for the general consumer market.

The Alternext Paris listing demonstrates ONI's confidence in the success of the launching of EvoraPlus[™] and its willingness to be seen as a major and long-term player through the future marketing of its other products in the United States and internationally.

Copies of the Information Document published by ONI in connection with its listing on Alternext Paris may be obtained free of charge from ONI at 13700 Progress Blvd., Alachua, Florida 32615, U.S.A. and from its Listing Sponsor, Bryan, Garnier & Co Ltd, at 36 Queen Street, London EC4R 1BN, United Kingdom, and at 33, avenue de Wagram, 75017 Paris, France, and on the websites of ONI (www.onibiopharma.com) and Alternext Paris (www.alternext.com).

¹ NYSE Alternext US LLC is the new name of The American Stock Exchange, which was acquired by NYSE Euronext on October 1, 2008.

Identification codes of ONI's shares on Alternext Paris:

- ISIN Code: US6840231046
- Ticker Symbol: ALONI

Listing sponsor:

Bryan, Garnier & Co Ltd

About ONI BioPharma

Oragenics, Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical company with a pipeline of unique proprietary technologies, some of which are being commercialized. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies with respect to its products, thereby creating a pipeline of future products, which the Company expects to develop.

ONI BIOPHARMA is listed on Alternext US (Ticker : ONI) and on Alternext Paris (Ticker : ALONI), exchanges of the NYSE Euronext group.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements that reflect ONI BioPharma's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements and draw the attention of investors to the risk factors described in the Information Document.

This press release does not constitute the offering of any securities for sale. The Company's securities may not be offered or sold absent registration under applicable securities laws or an exemption from registration. Any public offering of the securities of the Company will be made by means of a prospectus that will contain detailed information about the offering and the Company.

Contacts

ONI BioPharma Inc.
Executive Offices
Stanley B. Stein
Tel.: +1 386 418 4018
Extension 222
sstein@onibiopharma.com

Bryan, Garnier & Co Ltd
Listing Sponsor
Christian Finan
Tel.: + 33 (0)1 56 68 75 20
cfinan@bryangarnier.com

NewCap.
Financial Communication and Investor Relations
Axelle Vuillermet / Pierre Laurent
Tel.: + 33 (0)1 44 71 94 94
oni@newcap.fr

Rubenstein Communications, Inc.
Press Relations
Rhea Basroon
Tel.: + 1 212 843 8004
rbasroon@rubenstein.com

Strategic Growth International, Inc.
Investor Relations
Jennifer Zimmons
Tel.: + 1 917 214-3514
jzimmons@sgi-ir.com